The Arctic Front Advance cardiac cryoballoon from Medtronic received both FDA and CE Mark approvals, guaranteeing that it will soon eclipse the previous generation Arctic Front device on both sides of the Atlantic.
The Arctic Front Advance is indicated for use in the treatment of paroxysmal atrial fibrillation (PAF). Its primary improvement on the previous Arctic Front is the introduction of EvenCool Cryo Technology that distributes coolant more efficiently within while increasing the effective surface area of the balloon. The company believes the advancement will help surgeons isolate pulmonary veins that are typically ablation targets in atrial fibrillation treatment.
Components of the Arctic Front Advance system:
- The Arctic Front Advance Cryoballoon, which inflates and fills with coolant to ablate the tissue where the pulmonary veins enter the left atrium;
- The FlexCath® Steerable Sheath, which helps deliver and position the cryocatheter in the left atrium;
- The Achieve® Mapping Catheter, an intra-cardiac electrophysiology recording catheter used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation;
- The Freezor® MAX Cardiac CryoAblation Catheter, which is a single-point catheter used to provide additional ablations, as needed; and
- The CryoConsole, which houses the coolant, electrical and mechanical components that run the catheters during a cryoablation procedure.